Comparative Pharmacology
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 10MEQ versus MAGNESIUM SULFATE.
Head-to-head clinical analysis: DEXTROSE 5 SODIUM CHLORIDE 0 2 AND POTASSIUM CHLORIDE 10MEQ versus MAGNESIUM SULFATE.
DEXTROSE 5%, SODIUM CHLORIDE 0.2% AND POTASSIUM CHLORIDE 10MEQ vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dextrose provides calories and serves as a source of energy through cellular glucose uptake and metabolism. Sodium chloride replenishes extracellular fluid and electrolytes. Potassium chloride replaces intracellular potassium, essential for neuromuscular and cardiac function.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Intravenous infusion: 100-200 mL/hour, adjusting based on patient's fluid status, serum electrolytes, and clinical response. Typical administration rate for maintenance: 0.5-1.5 mL/kg/hour.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Dextrose: 1-2 hours (endogenous glucose turnover). Potassium: ~4-6 hours in healthy adults; prolonged in renal impairment.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Renal: Dextrose is metabolized to CO2 and water; sodium and potassium are excreted renally. Potassium excretion is 90% renal, 10% fecal. Sodium excretion is >95% renal.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte